MEI Pharma Inc (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced on 06 May 2014 that the first patient has been dosed in a Phase Ib clinical study of its investigational mitochondrial inhibitor drug candidate ME-344 in combination with Hycamtin® (topotecan) in patients with solid tumors, including small cell lung and ovarian cancers. The open-label study is expected to enroll up to 64 patients with preliminary data anticipated by the first quarter of 2015. MEI Pharma Inc (NASDAQ:MEIP) weekly performance is -12.43%. On last trading day company shares ended up $6.06. Analysts mean target price for the company is $15.75. MEI Pharma Inc (NASDAQ:MEIP) distance from 50-day simple moving average (SMA50) is -33.98%.
Pernix Therapeutics Holdings Inc (NYSE:PTX) major shareholder James Edward Jr. Smith sold 310,200 shares of Pernix Therapeutics Holdings Inc (NYSE:PTX) stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $6.12, for a total transaction of $1,898,424.00. Following the sale, the insider now directly owns 3,693,104 shares of the company’s stock, valued at approximately $22,601,796. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) shares fell -1.56% in last trading session and ended the day on $6.33. PTX Gross Margin is 50.20% and its return on assets is -11.20%. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) quarterly performance is 128.52%.
Dynavax Technologies Corporation (NASDAQ:DVAX) plunged -12.16% on 09 May 2014 after the company reported a loss of 5 cents per share in the first quarter of 2014, in line with the analyst’s Consensus Estimate. The loss reported in the year-ago quarter was 11 cents per share. Dynavax Technologies Corporation (NASDAQ:DVAX) reported revenues of $3.5 million, up 67.8% from the year-ago period and was in line with the analyst’s Consensus Estimate. Dynavax Technologies Corporation (NASDAQ:DVAX) shares moved down -0.76% in last trading session and was closed at $1.31, while trading in range of $1.26 – $1.36. Dynavax Technologies Corporation (NASDAQ:DVAX) year to date (YTD) performance is -33.16%.
Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s rating of “fair value” was reaffirmed by investment analysts at MKM Partners in a recently release research report and at present they have a price target of $1.50 on the company’s stock which is less from its earlier price target of $2.00. Amarin Corporation plc (ADR) (NASDAQ:AMRN) ended the last trading day at $1.37. Company weekly volatility is calculated as 5.49% and price to cash ratio as 1.23. Amarin Corporation plc (ADR) (NASDAQ:AMRN) showed a negative weekly performance of -9.60%.